Emergency medical care providing to patients with bradykinin-induced angioedema
Abstract
Emergency physicians come across patients with angioedema (AO) in their practice quite often. Depending on the mediator involved, various forms of AO forms can be recognized, calling for completely different therapeutic approaches. Despite of the similarity manifestations distinct AO caused by different mediators result in totally different prognosis for the patient. Prompt diagnosing is challenging for the emergency physician, but it is critical in patients’ outcomes. Low awareness of physicians in emergency department about rare bradykinin-mediated AO, which torpid to the standard regimens of therapy with adrenaline, systemic corficosteroids and antihistamines, adds to the problem. Lack of timely pathogenetic based therapeutic approaches can result in unjustified surgery, disability or death for patient.
About the Authors
T. V. Latysheva
National Research Center - Institute of Immunology
Russian Federation
Russian Federation
E. A. Latysheva
National Research Center - Institute of Immunology
Russian Federation
Russian Federation
I. A. Martynova
National Research Center - Institute of Immunology
Russian Federation
Russian Federation
References
1. Клиническая иммунология и аллергология. Федеральные клинические рекомендации. Под редакцией: акад. РАН Р. М. Хаитова, проф. Н. И. Ильиной.- Москва: «Фармус Принт Медиа», 2015, с. 37-52.
2. Аллергология и Иммунология национальное руководство, краткое издание. Под редакцией Хаитова Р. М. и Ильиной Н. И. Москва, «Гэотар-медиа», 2013, с. 482-493.
3. Аллергология. Федеральные клинические рекомендации. Главные редакторы: акад. РАН Р. М. Хаитов, проф. Н. И. Ильина. - Москва: ((Фармус Принт Медиа», 2014, с. 47-68.
4. Аллергология. Фармакотерапия без ошибок. Руководство для врачей под редакцией Р. М. Хаитова.-Москва: Е-ното, 2013. 277-287.
5. Wilkerson RG. Angioedema in the emergency department: an evidence-based review. Emerg Med Pract. 2012 Nov; 14 (11): 1-21. Epub 2012 Oct 20.
6. Cicardi M, Bellis P, Bertazzoni G, Cancian M, Chiesa M, Cremonesi P, Marino P, Montano N, Morselli C, Ottaviani F, Perricone R, Triggiani M, Zanichelli A. Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med. 2014 Feb; 9 (1): 85-92. doi: 10.1007/s11739-013-0993-z. Epub 2013 Sep 4.
7. Bernstein JA, Moellman J. Emerging concepts in the diagnosis and treatment of patients with undifferentiated angioedema. Int J Emerg Med. 2012 Nov6; 5 (1): 39. doi: 10.1186/1865-1380-5-39.
8. Obtutowicz K. Bradykinin-mediated angioedema. Pol Arch Med Wewn. 2016; 126 (1-2): 76-85. doi: http://dx.doi.org/10.20452/pamw.3273.
9. CicardiM, Suffritti C, Perego F, Caccia S. Novelties in the Diagnosis and Treatment of Angioedema. J Investig Allergol Clin Immunol. 2016; 26 (4): 212-21; quiz two pages after page 221. doi: 10.18176/jiaci.0087.
10. Bas M, Adams V, Suvorava T, Niehues T, Hoffmann TK, Kojda G. Nonallergic angioedema: role of bradykinin. Allergy. 2007 Aug; 62 (8): 842-56.
11. Kim SJ, Brooks JC, Sheikh J, Kaplan MS, Goldberg BJ. Angioedema deaths in the United States, 1979-2010. Ann Allergy Asthma Immunol. 2014 Dec; 113 (6): 630-4. doi: 10.1016/j. anai.2014.09.003. Epub 2014 Oct3.
12. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C 1-INH deficiency. J Allergy Clin Immunol. 2012 Sep; 130 (3): 692-7. doi: 10.1016/j. jaci.2012.05.055. Epub 2012 Jul28.
13. Global atlas of allergy published by the European Academy of allergy and clinical immulogy. Edotors Cezmi A. Akdis Ioana Agache. 2014 p. 212-214.
14. Craig T, Aygören-Pürsün E, Bork K, Bowen T, Boysen H, Farkas H, Grumach A, Katelaris CH, Lockey R, Longhurst H, Lumry W, Magerl M, Martinez-Saguer I, Ritchie B, Nast A, Pawankar R, Zuraw B, Maurer M. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J. 2012 Dec; 5 (12): 182-99. doi: W.W97/WOX.0b013e318279affa.
15. Caballero T, Baeza ML, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C, Gonzälez-Quevedo T, Guilarte M, Jurado-Palomo GJ, Larco JI, Lopez-Serrano MC, Lopez-Trascasa M, Marcos C, Munoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A; Spanish Study Group on Bradykinin- Induced Angioedema; Grupo Espanol de Estudio del Angioedema mediado por Bradicinina. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011; 21 (5): 333-17; quiz follow3 47.
16. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B; HAWK under the patronage of EAACI (European Academy of Allergy and Clinical Immunology). Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014 May; 69 (5): 602-16. doi: 10.1111/all.12380. Epub 2014 Mar 27.
17. Ali, M. A., & Borum, M. L. (2014). Hereditary angioedema: what the gastroenterologist needs to know. Clinical and Experimental Gastroenterology, 7, 435-445. http://doi.org/10.2147/ CEG.S 50465
18. Rubinstein, E., Stolz, L. E., Sheffer, A. L., Stevens, C., & Bousvaros, A. (2014). Abdominal attacks and treatment in hereditary angioedema with C 1-inhibitor deficiency. BMC Gastroenterology, 14, 71.
19. Bork K. Pasteurized and nanofiltered, plasma-derived C 1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy. 2014; 6 (5): 533-51. doi: 10.2217/ imt.14.33. Epub 2014 Mar 17.
20. Caballero T, Baeza ML, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C, Gonzälez- Quevedo T, Guilarte M, Jurado-Palomo J, Larco JI, Lopez-Serrano MC, Lopez-Trascasa M, Marcos C, Munoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A; Spanish Study Group on Bradykinin- Induced Angioedema (SGBA). Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations. J Investig Allergol Clin Immunol. 2011; 21 (6): 422-11; quiz 442-3.
21. Фиразир. Официальная инструкция к препарту.
22. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, Reshef A, Zuraw B; HAWK (Hereditary Angioedema International Working Group).Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C 1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012 Feb; 67 (2): 147-57. doi: 10.1111/j.1398-9995.2011.02751.x. Epub 2011 Nov 30.
23. Heather Minto; Kelly M. Maples A Case Series Of Seven Pediatric Patients Successfully Treated With Ecallantide and Icatibant For Hereditary Angioedema The Journal of Allergy and Clinical Immunology. 133 (2): AB33, Feb 2014 DOI: 10.1016/j.jaci.2013.12.144
24. Zanichelli A, Mansi M, Periti G. Icatibant Exposure During Pregnancy in a Patient With Hereditary Angioedema. J Investig Allergol Clin Immunol. 2015; 25 (6): 447-9.
25. Farkas, H., Köhalmi, K. V., Veszeli, N., Toth, F., and Varga, L. (2016) First report of icatibant treatment in a pregnant patient with hereditary angioedema. J. Obstet. Gynaecol. Res., 42: 1026-1028. doi: 10.1111/jog.13003.
26. Karine Boufieur, Luana Delcaro; and 9 more Successful and Safe Use Of Icatibant For Life-Threatening Angioedema Attack During Pregnancy In a Patient With Hereditary Angioedema Type I The Journal of Allergy and Clinical Immunology. 133 (2): AB36, Feb 2014 DOI: 10.1016/j. jaci.2013.12.153.
27. https://clinicaltrials.gov/ctZ/show/NCT01034969.
28. Беринерт. Официальная инструкция к препарату.
29. Постановление Правительства РФ от 26 апреля 2012 г. N403 «О порядке ведения Федерального регистра лиц, страдающих жизнеугрожающими и хроническими прогрессирующими редкими (орфанными) заболеваниями, приводящими к сокращению продолжительности жизни граждан или их инвалидности, и его регионального сегмента». http://giod.consultant.ru/documents/1609501.
30. Ba§ M, Greve J, Stelter K, Havel M, Strassen U, Rotter N, Veit J, Schossow B, Hapfelmeier A, Kehl V, Kojda G, Hoffmann TK. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. N Engl J Med. 2015 Jan 29; 372 (5): 418-25. doi: 10.1056/NEJMoa1312524.
31. Fok JS, Katelaris CH, Brown AF, Smith WB. Icatibant in angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. Intern Med J. 2015 Aug; 45 (8): 821-7. doi: 10.1111/imj.12799.
32. Bova M, Guilarte M, Sala-Cunill A, Borrelli P, Rizzelli GM, Zanichelli A. Treatment of ACEI-related angioedema with icatibant: a case series. Intern Emerg Med. 2015 Apr; 10 (3): 345-50. doi: 10.1007/s11739-015-1205-9. Epub 2015 Feb 10.
33. Scalese MJ, Reinaker TS. Pharmacologic management of angioedema induced by angiotensin-converting enzyme inhibitors. Am J Health Syst Pharm. 2016 Jun 15; 73 (12): 873-9. doi: 10.2146/ajhp150482.
34. Warrier MR, Copilevitz CA, Dykewicz MS, Slavin RG. Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema. Ann Allergy Asthma Immunol. 2004 May; 92 (5): 573-5.
Review
For citations:
Latysheva T.V., Latysheva E.A., Martynova I.A. Emergency medical care providing to patients with bradykinin-induced angioedema. Medical alphabet. 2017;1(5):33-39. (In Russ.)
Views:
337
Email this article 